Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
Stephen Schey(University College Hospital), Angus Dalgleish(St George's, University of London), Matthew Streetly(King's College - North Carolina), Paul Fields(St Thomas' Hospital), Ian Clarke(St George's Hospital), Robert Knight(King's College London), J. Blake Bartlett(St George's Hospital), G. Ashan(St George's Hospital)
Cited by 315
Related Papers
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
|Blood|2010|866
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614